Breaking News

CDC Advisors Examine Link Between Heart Inflammation and COVID mRNA Injections | Business and Economy News


The United States Centers for Disease Control and Prevention identified a total of 216 cases of heart inflammation after the first dose of an mRNA injection, and a further 573 cases after the second dose.

Through Bloomberg

U.S. public health advisers will meet to discuss a potential link between Covid-19 injections that use messenger RNA technology and heart inflammation after hundreds of vaccinated people suffered from a disease called myocarditis.

The Centers for Disease Control and Prevention’s advisory committee on immunization practices will meet on June 18 to discuss an increase in reported cases of the disease, particularly among adolescents and young adults. Covid vaccines manufactured by Moderna Inc. and its partners Pfizer Inc. and BioNTech SE use mRNA technology.

Since April, the CDC has seen an increase in the number of cases of myocarditis and pericarditis, an inflammation of the membrane around the heart. The cases, although rare, have occurred mainly in adolescents and young adults.

The CDC has identified a total of 216 cases of heart inflammation after the first dose of an mRNA injection, and a further 573 cases after the second dose. The median age of people with myocarditis or pericarditis after the first dose was 30 years and 24 years among the second dose cases. There have been 475 cases identified among those under 30.

Most patients responded well to treatment and to rest, according to the agency, and more than 8 in 10 had complete relief from their symptoms. The agency examines cases by age in more detail.

About 130 million Americans have received the full two-dose regimen of one of two licensed mRNA vaccines. Many teens have now received their first dose of the Pfizer-BioNTech vaccine, which was released for teens 12 and older on May 10.

“We’re still learning about the rates of myocarditis and pericarditis,” Tom Shimabukuro, a safety expert with the CDC’s National Center for Emerging Infectious Diseases and Zoonotic Diseases, said Thursday at a Food and Drug panel meeting. Administration. “As we gather more information we will start to get a better idea of ​​post-vaccination rates and hope to be able to get more detailed information by age group.”

Shimabukuro said the US data is consistent with findings from Israel’s vaccinated population.

“It’s hard to deny that there is an event that appears to be happening,” Cody Meissner, chief of the pediatric infectious disease division at Tufts Medical Center, said at the FDA advisory committee meeting on Thursday.



Leave a Reply